Tearsheet

BioNTech (BNTX)

Market Price (9/4/2025): $100.0 | Market Cap: $24.2 Bil
Sector: Health Care | Industry: Biotechnology

BioNTech (BNTX)

Market Price (9/4/2025): $100.0
Market Cap: $24.2 Bil
Sector: Health Care
Industry: Biotechnology

Market Valuation

	9/4/25	2024	2023	2022	2021
Share Price CYE	$100.00	$113.95	$105.54	$150.22	$254.43
Market Cap CYE ($ Bil)	24.2	27.0	25.3	36.8	62.2
Total Debt ($ Bil)	0.3	0.3	0.2	0.2	0.3
Total Cash ($ Bil)	14.0	16.8	16.5	14.1	2.1
Enterprise Value ($ Bil)	10.4	27.3	25.5	37.0	62.5
Valuation Ratios
P/S TTM	8.4	10.0	6.7	2.1	3.3
P/EBIT TTM	-70.0	-41.2	21.3	2.8	4.2
P/E TTM	-70.1	-41.2	27.3	3.9	6.1
Sector Ratios
P/S TTM (Sector)	3.8	4.1	4.5	4.5	6.7
P/EBIT TTM (Sector)	4.3	0.4	-1.9	-1.2	-0.4
P/E TTM (Sector)	-1.8	-2.2	-3.4	-2.2	-2.3

	9/4/25	2024	2023
Share Price CYE	$100.00	$113.95	$105.54
Market Cap CYE ($ Bil)	24.2	27.0	25.3
Total Debt ($ Bil)	0.3	0.3	0.2
Total Cash ($ Bil)	14.0	16.8	16.5
Enterprise Value ($ Bil)	10.4	27.3	25.5
Valuation Ratios
P/S TTM	8.4	10.0	6.7
P/EBIT TTM	-70.0	-41.2	21.3
P/E TTM	-70.1	-41.2	27.3
Sector Ratios
P/S TTM (Sector)	3.8	4.1	4.5
P/EBIT TTM (Sector)	4.3	0.4	-1.9
P/E TTM (Sector)	-1.8	-2.2	-3.4

Stock Price
Market Cap

Stock Price Chart

Return (1Y):

Market Cap Chart

Business Description

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. Show more BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany. Show less

Price Returns Compared

Expand for Detailed View

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
BNTX Return	141%	216%	-41%	-30%	8%	-12%	253%
Peers Return	90%	55%	6%	-15%	-6%	3%	156%
S&P 500 Return	16%	27%	-19%	24%	23%	10%	100%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: AMGN, PFE, MRNA, ABBV, GILD.
[3] 2025 data is for the year up to 9/3/2025 (YTD)

Latest Trefis Analyses

	Title	Topic	Date
0	DASHBOARDS
1	BioNTech SE (BNTX) Stock Has 60% Chance Of Rise In The Next One Month	Chance of Rise
2	[10/21/2022] BioNTech SE (BNTX) Shares Moved 11% Today (4% likelihood event)
3	Dates Cached For BNTX
4	BioNTech SE (BNTX) Stock Has 63% Chance Of Rise In The Next One Month	Chance of Rise
5	BioNTech SE (BNTX) Stock Has 63% Chance Of Rise In The Next One Month	Chance of Rise
6	BioNTech: Highest And Lowest Correlated Assets	Correlation
7	BioNTech To S&P 500 Ratio	Ratios
8	BioNTech Trading Activity	Technicals
9	BioNTech Market Momentum	Technicals
10	BioNTech Excess Market Return vs S&P 500
11	ARTICLES
12	What’s Happening With BioNTech Stock?		January 19th, 2022
13	Down 34% Last Month, Should You Buy BioNTech Stock For Near-Term Gains?		October 18th, 2021
14	What’s New With BioNTech Stock?		September 28th, 2021
15	What Drove BioNTech Stock’s Incredible Rise From $80 To $420 This Year?		August 11th, 2021
16	What’s Happening With BioNTech Stock?		July 7th, 2021

	Title
0	DASHBOARDS
1	What’s Happening With BioNTech Stock?
2	Down 34% Last Month, Should You Buy BioNTech Stock For Near-Term Gains?
3	What’s New With BioNTech Stock?
4	What Drove BioNTech Stock’s Incredible Rise From $80 To $420 This Year?
5	What’s Happening With BioNTech Stock?
6	ARTICLES
7	BioNTech SE (BNTX) Stock Has 60% Chance Of Rise In The Next One Month
8	[10/21/2022] BioNTech SE (BNTX) Shares Moved 11% Today (4% likelihood event)
9	Dates Cached For BNTX
10	BioNTech SE (BNTX) Stock Has 63% Chance Of Rise In The Next One Month
11	BioNTech SE (BNTX) Stock Has 63% Chance Of Rise In The Next One Month
12	BioNTech: Highest And Lowest Correlated Assets
13	BioNTech To S&P 500 Ratio
14	BioNTech Trading Activity
15	BioNTech Market Momentum
16	BioNTech Excess Market Return vs S&P 500

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	XELA	Exela Technologies	212.4%	-95.5%
2	TKCM	Token Communities	82.8%	-64.7%
3	ANGGF	Angang Steel	61.2%	25.0%
4	BATMF	British American Tobacco Malaysia	43.4%	59.2%
5	KYSEF	Kyushu Electric Power	32.1%	32.1%
6	STTK	Shattuck Labs	26.7%	5.8%
7	KTHAF	Krung Thai Bank	24.0%	24.0%
8	SFOSF	Shanghai Fosun Pharmaceutical	23.7%	61.7%
9	INDOY	Indorama Ventures	20.9%	-5.5%
10	M	Macy's	20.7%	-1.0%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
2	MGAWF	Megaworld	-71.0%	-71.0%
3	PTTMF	PT Timah	-62.8%	-83.1%
4	PTJSF	PT Jasa Marga	-50.9%	-50.9%
5	UNLRF	PT Unilever Indonesia	-41.3%	-17.6%
6	DLNDY	D&L Industries	-37.5%	-30.7%
7	SUCEF	Sumitomo Osaka Cement	-37.4%	-37.4%
8	PTKFF	PT Kalbe Farma	-34.7%	-32.1%
9	SMTGF	SMA Solar Technology	-30.1%	28.4%
10	PMDKF	PT Mitra Adiperkasa	-28.6%	-48.9%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	EAF	GrafTech International	804.0%	-47.2%
2	RLMD	Relmada Therapeutics	122.3%	182.7%
3	XELA	Exela Technologies	109.6%	-95.5%
4	PSNYW	Polestar Automotive UK	96.2%	141.5%
5	TKCM	Token Communities	82.8%	-64.7%
6	PHJMF	PT Hanjaya Mandala Sampoerna	66.7%	34.8%
7	ANGGF	Angang Steel	61.2%	25.0%
8	DTNOF	DNO	49.5%	141.9%
9	BW	Babcock & Wilcox Enterprises	48.5%	54.9%
10	MDB	MongoDB	46.0%	34.4%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	COSG	Grand Gallery	-100.0%	�
2	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
3	NXTT	Next Technology	-74.5%	-89.4%
4	SCGY	Scientific Energy	-72.7%	-26.9%
5	MGAWF	Megaworld	-71.0%	-71.0%
6	TTOO	T2 Biosystems	-67.7%	-99.0%
7	PTTMF	PT Timah	-62.8%	-83.1%
8	PIGEF	Pigeon	-62.4%	-62.4%
9	NEGG	Newegg Commerce	-53.8%	290.6%
10	PTJSF	PT Jasa Marga	-50.9%	-50.9%

1 Month Top Gainers

#	Ticker	Company	1M Rtn	YTD Rtn
1	MMEX	MMEX Resources	∞%	-50.0%
2	TAWNF	Thai Airways International	3674.5%	3400.0%
3	NOKPF	Nok Airlines	2400.0%	81.8%
4	AYRWF	Ayr Wellness	509.5%	-94.6%
5	XELA	Exela Technologies	379.0%	-95.5%
6	SRNE	Sorrento Therapeutics	233.3%	900.0%
7	PGEN	Precigen	169.9%	324.1%
8	TLS	Telos	154.7%	89.2%
9	SATS	EchoStar	142.7%	179.1%
10	RLMD	Relmada Therapeutics	139.0%	182.7%

1 Month Top Losers

#	Ticker	Company	1M Rtn	YTD Rtn
1	COSG	Grand Gallery	-100.0%	�
2	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
3	TTOO	T2 Biosystems	-94.8%	-99.0%
4	NXTT	Next Technology	-86.5%	-89.4%
5	OTRK	Ontrak	-78.2%	-96.6%
6	SCGY	Scientific Energy	-72.7%	-26.9%
7	PPCB	Propanc Biopharma	-72.1%	-79.1%
8	MGAWF	Megaworld	-71.0%	-71.0%
9	PTTMF	PT Timah	-62.8%	-83.1%
10	PIGEF	Pigeon	-62.4%	-62.4%

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	XELA	Exela Technologies	212.4%	-95.5%
2	TKCM	Token Communities	82.8%	-64.7%
3	ANGGF	Angang Steel	61.2%	25.0%
4	BATMF	British American Tobacco Malaysia	43.4%	59.2%
5	KYSEF	Kyushu Electric Power	32.1%	32.1%
6	STTK	Shattuck Labs	26.7%	5.8%
7	KTHAF	Krung Thai Bank	24.0%	24.0%
8	SFOSF	Shanghai Fosun Pharmaceutical	23.7%	61.7%
9	INDOY	Indorama Ventures	20.9%	-5.5%
10	M	Macy's	20.7%	-1.0%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
2	MGAWF	Megaworld	-71.0%	-71.0%
3	PTTMF	PT Timah	-62.8%	-83.1%
4	PTJSF	PT Jasa Marga	-50.9%	-50.9%
5	UNLRF	PT Unilever Indonesia	-41.3%	-17.6%
6	DLNDY	D&L Industries	-37.5%	-30.7%
7	SUCEF	Sumitomo Osaka Cement	-37.4%	-37.4%
8	PTKFF	PT Kalbe Farma	-34.7%	-32.1%
9	SMTGF	SMA Solar Technology	-30.1%	28.4%
10	PMDKF	PT Mitra Adiperkasa	-28.6%	-48.9%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	EAF	GrafTech International	804.0%	-47.2%
2	RLMD	Relmada Therapeutics	122.3%	182.7%
3	XELA	Exela Technologies	109.6%	-95.5%
4	PSNYW	Polestar Automotive UK	96.2%	141.5%
5	TKCM	Token Communities	82.8%	-64.7%
6	PHJMF	PT Hanjaya Mandala Sampoerna	66.7%	34.8%
7	ANGGF	Angang Steel	61.2%	25.0%
8	DTNOF	DNO	49.5%	141.9%
9	BW	Babcock & Wilcox Enterprises	48.5%	54.9%
10	MDB	MongoDB	46.0%	34.4%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	COSG	Grand Gallery	-100.0%	�
2	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
3	NXTT	Next Technology	-74.5%	-89.4%
4	SCGY	Scientific Energy	-72.7%	-26.9%
5	MGAWF	Megaworld	-71.0%	-71.0%
6	TTOO	T2 Biosystems	-67.7%	-99.0%
7	PTTMF	PT Timah	-62.8%	-83.1%
8	PIGEF	Pigeon	-62.4%	-62.4%
9	NEGG	Newegg Commerce	-53.8%	290.6%
10	PTJSF	PT Jasa Marga	-50.9%	-50.9%

Peer Comparisons for BioNTech

Financials

	BNTX	AMGN	PFE	MRNA	ABBV	GILD	Median
Name	BioNTech	Amgen	Pfizer	Moderna	AbbVie	Gilead S.
Mkt Price	-	286.92	24.98	24.19	211.92	112.71	112.71
Mkt Cap	-	154.4	142.0	9.4	374.7	140.3	142.0
Rev LTM	-	34,917	63,833	3,055	58,328	28,862	34,917
Op Inc LTM	-	8,192	16,663	-3,273	13,695	10,797	10,797
FCF LTM	-	10,605	12,438	-3,500	18,239	9,369	10,605
FCF 3Y Avg	-	8,590	9,304	-2,744	20,273	8,397	8,590
CFO LTM	-	12,013	15,188	-2,697	19,283	9,868	12,013
CFO 3Y Avg	-	9,753	12,584	-2,055	21,154	8,949	9,753

Growth & Margins

	BNTX	AMGN	PFE	MRNA	ABBV	GILD	Median
Name	BioNTech	Amgen	Pfizer	Moderna	AbbVie	Gilead S.
Rev Chg LTM	-	12.9%	13.5%	-38.8%	6.1%	3.8%	6.1%
Rev Chg 3Y Avg	-	10.0%	-12.4%	-48.0%	0.6%	1.6%	0.6%
Rev Chg Q	-	9.4%	10.3%	-38.0%	6.6%	1.8%	6.6%
QoQ Delta Rev Chg LTM	-	2.3%	2.2%	-2.7%	1.7%	0.4%	1.7%
Op Mgn LTM	-	23.5%	26.1%	-107.1%	23.5%	37.4%	23.5%
Op Mgn 3Y Avg	-	26.4%	20.2%	-65.1%	27.2%	39.2%	26.4%
QoQ Delta Op Mgn LTM	-	1.6%	1.8%	11.7%	1.0%	-0.0%	1.6%
CFO/Rev LTM	-	34.4%	23.8%	-88.3%	33.1%	34.2%	33.1%
CFO/Rev 3Y Avg	-	32.0%	18.8%	-51.8%	37.5%	31.9%	31.9%
FCF/Rev LTM	-	30.4%	19.5%	-114.6%	31.3%	32.5%	30.4%
FCF/Rev 3Y Avg	-	28.2%	13.8%	-67.2%	36.0%	30.0%	28.2%

Valuation

	BNTX	AMGN	PFE	MRNA	ABBV	GILD	Median
Name	BioNTech	Amgen	Pfizer	Moderna	AbbVie	Gilead S.
Mkt Cap	-	154.4	142.0	9.4	374.7	140.3	142.0
P/S	-	4.4	2.2	3.1	6.4	4.9	4.4
P/EBIT	-	14.9	10.6	-3.2	63.6	17.1	14.9
P/E	-	23.3	13.2	-3.2	99.6	22.2	22.2
P/CFO	-	12.8	9.4	-3.5	19.4	14.2	12.8
Total Yield	-	7.5%	12.7%	-30.9%	4.0%	7.3%	7.3%
Dividend Yield	-	3.2%	5.1%	0.0%	3.0%	2.8%	3.0%
FCF Yield 3Y Avg	-	6.2%	5.7%	-14.3%	7.3%	8.0%	6.2%
D/E	-	0.4	0.4	0.1	0.2	0.2	0.2
Net D/E	-	0.3	0.3	-0.5	0.2	0.1	0.2

Returns

	BNTX	AMGN	PFE	MRNA	ABBV	GILD	Median
Name	BioNTech	Amgen	Pfizer	Moderna	AbbVie	Gilead S.
1M Rtn	-	-2.6%	6.3%	-12.4%	8.6%	-0.4%	-0.4%
3M Rtn	-	-0.1%	8.8%	-13.0%	14.2%	3.8%	3.8%
6M Rtn	-	-6.5%	0.6%	-20.3%	3.8%	-0.4%	-0.4%
12M Rtn	-	-11.2%	-7.8%	-68.7%	11.8%	47.3%	-7.8%
3Y Rtn	-	30.3%	-35.6%	-82.5%	74.1%	97.4%	30.3%
1M Excs Rtn	-	-5.4%	3.5%	-15.2%	5.7%	-3.3%	-3.3%
3M Excs Rtn	-	-7.8%	0.2%	-18.7%	6.2%	-3.9%	-3.9%
6M Excs Rtn	-	-15.8%	-11.0%	-29.8%	-7.7%	-11.1%	-11.1%
12M Excs Rtn	-	-24.7%	-21.7%	-83.9%	-2.4%	33.4%	-21.7%
3Y Excs Rtn	-	-24.3%	-91.3%	-135.8%	17.5%	45.4%	-24.3%

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End		12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date		3/10/2025	3/20/2024	3/27/2023	3/30/2022	3/30/2021	3/31/2020
Key Financials
Total Revenue	2,878	2,751	3,819	17,311	18,977	482	109
Ebitda	-42	-367	1,377	13,096	15,002	-105	-144
Operating Income	-135	-596	904	12,304	14,927	-82	-182
Net Income	-345	-665	930	9,434	10,292	15	-179
EPS	-1.43	-2.77	3.87	38.78	42.18	0.06	-0.85
Growth Rates
Total Revenue Growth	7.0%	-28.0%	-77.9%	-8.8%	3834.6%	344.1%	-14.9%
EBITDA Growth	-64.7%	-126.7%	-89.5%	-12.7%	14374.3%	26.9%	-500.2%
Operating Income Growth	65.2%	-165.9%	-92.7%	-17.6%	18215.4%	54.6%	-236.7%
Net Income Growth	31.6%	-171.5%	-90.1%	-8.3%	67613.8%	108.5%	-273.0%
Margins
EBITDA Margin	-1.4%	-13.3%	36.1%	75.7%	79.1%	-21.8%	-132.4%
Operating Income Margin	-4.7%	-21.7%	23.7%	71.1%	78.7%	-17.1%	-167.1%
Net Income Margin	-12.0%	-24.2%	24.4%	54.5%	54.2%	3.2%	-164.9%
Cash & Debt
Total Cash	14,037	16,784	16,549	14,064	2,074	1,347	521
Total Debt	270	254	219	212	302	240	74
Net Debt / (Cash)	-13,767	-16,529	-16,330	-13,852	-1,773	-1,107	-447
Cash Flows
Net Cash from Operations	-1,736	208	5,371	13,577	890	-14	-198
Free Cash from Operations	-2,559	-245	4,666	13,214	736	-99	-270
Returns to Shareholders
Dividends	0	-0	-0	484	-0	-0	-0
Share Repurchases	-0	-0	738	986	-0	-0	-0

$ Mil \| FY: 12/31	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3
Period End	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Filing Date	8/4/2025	5/5/2025	3/10/2025	11/4/2024	8/5/2024	5/6/2024	3/20/2024	11/6/2023	8/7/2023	5/8/2023	3/27/2023	11/7/2022
Key Financials Quarterly
Total Revenue	261	183	1,190	1,245	129	188	1,479	895	168	1,277	4,278	3,461
Ebitda	-348	-369	464	211	-752	-289	745	271	-379	768	3,204	2,482
Operating Income	-478	-534	867	10	-694	-507	740	73	-563	654	3,462	2,221
Net Income	-387	-416	260	198	-808	-315	458	161	-190	502	2,279	1,785
EPS	-1.60	-1.73	1.08	0.82	-3.36	-1.31	1.91	0.67	-0.79	2.07	9.38	7.43
Key Financials TTM
Total Revenue TTM	2,878	2,746	2,751	3,040	2,691	2,730	3,819	6,618	9,184	12,213	17,311	18,565
Ebitda TTM	-42	-446	-366	-85	-25	348	1,405	3,864	6,075	8,409	12,694	14,108
Operating Income TTM	-135	-350	-323	-450	-388	-257	904	3,627	5,775	8,260	12,358	13,480
Net Income TTM	-345	-766	-665	-467	-504	113	930	2,751	4,375	6,238	9,434	10,322
Growth Rates Quarterly
Total Revenue Growth	102.6%	-2.6%	-19.5%	39.0%	-23.3%	-85.3%	-65.4%	-74.1%	-94.8%	-80.0%	-22.7%	-43.1%
EBITDA Growth	53.7%	-27.7%	-37.7%	-22.0%	-98.5%	-137.6%	-76.7%	-89.1%	-119.4%	-84.8%	-30.6%	-47.1%
Operating Income Growth	31.0%	-5.3%	17.2%	-85.6%	-23.1%	-177.5%	-78.6%	-96.7%	-129.3%	-86.2%	-24.5%	-51.3%
Net Income Growth	52.1%	-32.0%	-43.3%	23.3%	-324.3%	-162.7%	-79.9%	-91.0%	-111.4%	-86.4%	-28.0%	-44.4%
Margins Quarterly
EBITDA Margin	-133.6%	-201.7%	39.0%	17.0%	-584.7%	-153.9%	50.4%	30.2%	-226.0%	60.1%	74.9%	71.7%
Operating Income Margin	-183.5%	-292.2%	72.9%	0.8%	-538.9%	-270.4%	50.0%	8.2%	-335.9%	51.2%	80.9%	64.2%
Net Income Margin	-148.2%	-227.5%	21.8%	15.9%	-627.7%	-168.0%	31.0%	17.9%	-113.5%	39.3%	53.3%	51.6%
Cash & Debt
Total Cash	14,037	14,110	16,784	16,709	17,296	15,666	16,549	15,749	15,557	12,502	14,064	13,428
Total Debt	270	293	254	244	255	236	219	202	206	210	212	274
Net Debt / (Cash)	-13,767	-13,817	-16,529	-16,466	-17,041	-15,430	-16,330	-15,547	-15,352	-12,292	-13,852	-13,154
Cash Flows Quarterly
FCF from Operations	146	-781	-463	-639	1,627	-317	851	811	4,387	-677	829	4,779
Cash Flows TTM
FCF from Operations TTM	-1,736	-256	208	1,522	2,972	5,732	5,371	5,350	9,317	8,850	13,577	12,549
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	1	302	154	282	56	644
Return on Invested Capital (ROIC) Quarterly
ROIC	-	-	-	-	-	-	-	-	-	-	-	-
Return on Invested Capital (ROIC) TTM
ROIC TTM	-	-	-	-	-	-	-	-	-	-	-	-

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
Single Segment	3,819	17,311
Direct product sales to customers			3,007	21
Other sales			67	33	24
Research & development revenues from collaborations			103
Sales to collaboration partners			971	61
Share of collaboration partners’ gross profit and sales milestones			14,829	188
Genentech Inc.				49	64
Other				3	6
Pfizer Inc.				122	14
Shanghai Fosun Pharmaceutical (Group) Co., Ltd				5
Total	3,819	17,311	18,977	482	109

Price Behavior

Behavior Stats
Betas Matrix

Price Behavior

Market Price	$100.42
Market Cap ($ Bil)	24.3
First Trading Date	10/10/2019
Distance from 52W High	-20.9%
	50 Days	200 Days
DMA Price	$109.30	$108.40
DMA Trend	indeterminate	up
Distance from DMA	-8.1%	-7.4%
	3M	1YR
Volatility	23.8%	54.2%
Downside Capture	158.09	139.91
Upside Capture	36.95	130.72
Correlation (SPY)	19.9%	33.2%
	5D	10D
Expected Return	4.5%	4.1%
Expected Excess Return	3.5%	5.4%
Chance of Rise	56.5%	55.9%
Std Dev of Returns	2.8%	2.6%

BNTX Betas & Captures as of 8/31/2025

	1M	2M	3M	6M	1Y	3Y
Beta	0.94	1.12	0.98	0.87	0.91	0.79
Up Beta	1.36	0.77	0.38	0.98	0.92	0.85
Down Beta	-0.16	-0.06	-0.73	0.18	0.25	0.53
Up Capture	44%	98%	141%	105%	159%	39%
Bmk +ve Days	10	22	35	71	142	415
Stock +ve Days	9	18	27	52	112	344
Down Capture	204%	257%	204%	130%	121%	100%
Bmk -ve Days	11	19	27	54	106	334
Stock -ve Days	12	23	35	72	135	405

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date	8152025
Short Interest: Shares Quantity	6,315,487
Short Interest: % Change Since 7312025	4.4%
Average Daily Volume	708,083
Days-to-Cover Short Interest	8.92
Basic Shares Quantity	241,625,000
Short % of Basic Shares	2.6%

Returns Analyses

	Title
0	[10/10/2021] BioNTech SE (BNTX) Stock Price Forecast: AI Forecasts BNTX Stock Price To Be Around $289 In A Month (Up 18%)

SEC Filings

Expand for More

Report Date	Filing
6302025	6-K 6/30/2025
3312025	6-K 3/31/2025
12312024	20-F 12/31/2024
9302024	6-K 9/30/2024
6302024	6-K 6/30/2024
3312024	6-K 3/31/2024
12312023	20-F 12/31/2023
9302023	6-K 9/30/2023
6302023	6-K 6/30/2023
3312023	6-K 3/31/2023
12312022	20-F 12/31/2022
9302022	6-K 9/30/2022
6302022	6-K 6/30/2022
3312022	6-K 3/31/2022
12312021	20-F 12/31/2021
9302021	6-K 9/30/2021

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
BNTX Return	141%	216%	-41%	-30%	8%	-12%	253%
Peers Return	90%	55%	6%	-15%	-6%	3%	156%
S&P 500 Return	16%	27%	-19%	24%	23%	10%	100%
Monthly Win Rates [3]
BNTX Win Rate	67%	75%	42%	42%	50%
Peers Win Rate	53%	62%	50%	38%	52%	51%
S&P 500 Win Rate	58%	75%	42%	67%	75%	57%
Max Drawdowns [4]
BNTX Max Drawdown	-16%	0%	-53%	-39%	-26%	-2%
Peers Max Drawdown	-19%	-4%	-21%	-31%	-21%	-14%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

BioNTech (BNTX)

Market Price (9/4/2025): $100.0 | Market Cap: $24.2 BilSector: Health Care | Industry: Biotechnology

BioNTech (BNTX)

Market Price (9/4/2025): $100.0Market Cap: $24.2 BilSector: Health CareIndustry: Biotechnology

Investment Highlights

Market Valuation

Stock Price Chart

Market Cap Chart

Business Description

Price Returns Compared

Interactive Breakdown

Better Bets than BioNTech (BNTX)

Latest Trefis Analyses

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for BioNTech

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (9/4/2025): $100.0 | Market Cap: $24.2 Bil
Sector: Health Care | Industry: Biotechnology

Market Price (9/4/2025): $100.0
Market Cap: $24.2 Bil
Sector: Health Care
Industry: Biotechnology